Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:10
  • preuzimanja u poslednjih 30 dana:1
članak: 4 od 85  
Back povratak na rezultate
Vojnosanitetski pregled
2019, vol. 76, br. 5, str. 510-517
jezik rada: engleski
vrsta rada: originalan članak
doi:10.2298/VSP170114108M

Creative Commons License 4.0
Napredne tehnike magnetne rezonance u ranom razdvajanju pseudoprogresije od progresije kod bolesnika sa glioblastomom multiforme
aUniverzitet u Beogradu, Medicinski fakultet, Institut za onkologiju i radiologiju Srbije
bUniverzitet u Beogradu, Fakultet za fizičku hemiju

e-adresa: j.m.mihailovic@gmail.com

Sažetak

Uvod/Cilj. Uvođenje tretmana glioblastoma zračnom terapijom uz konkurentnu i adjuvantnu primenu temozolomida (CRT) dovelo je do pojave nove dijagnostičke dileme - potrebe za razlikovanjem pseudo-progresije i presudoodgovora. Razlikovanje snimaka magnetne resonance (MR) ova dva fenomena za sada je moguće samo evaluacijom u više vremenskih tačaka u toku terapije, dok nove tehnike koje bi pomogle u njihovom razlikovanju nisu još uvedene. U radu je analizirana mogućnost primene time-to-peak (TTP) mapa dinamičkog perfuzionog imidžinga i magnetno rezonantne spektroskopije u utvrđivanju odgovora tumora na terapiju. Metode. Analizirano je 40 bolesnika sa primarnim glioblastomom multiforme. Bolesnici su snimani u trećoj nedelji nakon operacije i desetoj nedelji od početka CRT. Pregledi na aparatu za Mr rađeni su na aparatu 1.5 T Avanto Siemens, Erlangen Nemačka. Mape perfuzionih parametara generisane su i analizirane korišćenjem programa DPtools v3.79. 3D CSI PRESS spektroskopija sa dugim i kratkim vremenom eha rađena je kod svih bolesnika. Rezultati. Kod 32 od 40 bolesnika dijagnostikovana je progresija bolesti, a kod osam je dijagnostikovana pseudo-progresija. Kod bolesnika sa progresijom bolesti dobijene time-to-peak vrednosti su bile 33 ± 7 s u trećoj nedelji i 30 ± 5 s u desetoj nedelji, što ne predstavlja statistički značajnu razliku. Vrednosti ovog parametra za pseudoprogresiju bile su 32 ± 8 s u trećoj i 43 ± 9 s u desetoj nedelji što je statistički značajna razlika (p < 0.05). Rezultati spektroskopije ukazali su na prisustvo glicinskog pika kod šest bolesnika sa progresijom bolesti, dok kod pseudoprogresije ovaj metabolit nije bio prisutan. Zaključak. Analizirani Mr snimci pokazali su da je Mr veoma uspešna tehniku za postavljanje dijagnoze progresije bolesti tokom terapije kod bolesnika sa glioblastomom.

Ključne reči

Reference

Baek, H.J., Kim, H.S., Kim, N.S., Choi, Y.J., Kim, Y.J. (2012) Percent Change of Perfusion Skewness and Kurtosis: A Potential Imaging Biomarker for Early Treatment Response in Patients with Newly Diagnosed Glioblastomas. Radiology, 264(3): 834-843
Barajas, R.F., Chang, J.S., Segal, M.R., Parsa, A.T., McDermott, M.W., Berger, M.S., Cha, S. (2009) Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Mr Imaging. Radiology, 253(2): 486-496
Brandes, A.a., Tosoni, A., Spagnolli, F., Frezza, G., Leonardi, M., Calbucci, F., Franceschi, E. (2008) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology. Neuro-Oncology, 10(3): 361-367
Carlsson, S.K., Brothers, S.P., Wahlestedt, C. (2014) Emerging treatment strategies for glioblastoma multiforme. EMBO Molecular Medicine, 6(11): 1359-1370
Cha, J., Kim, S.T., Kim, H.T., Kim, B.T., Kim, Y.K., Lee, J.Y., Jeon, P., Kim, K.H., Kong, D., Nam, D.H. (2014) Differentiation of Tumor Progression from Pseudoprogression in Patients with Posttreatment Glioblastoma Using Multiparametric Histogram Analysis. American Journal of Neuroradiology, 35(7): 1309-1317
Cha, S., Yang, L., Johnson, G., Lai, a., Chen, M.H., Tihan, T., i dr. (2006) Comparison of Microvascular Permeability Measurements, Ktrans, Determined with Conventional Steady-State T1-Weighted and First-Pass T2*-Weighted Mr Imaging Methods in Gliomas and Meningiomas. Am J Neuroradiol, 27(2): 40917-40917
Chinnaiyan, P., Kensicki, E., Bloom, G., Prabhu, a., Sarcar, B., Kahali, S., Eschrich, S., Qu, X., Forsyth, P., Gillies, R. (2012) The Metabolomic Signature of Malignant Glioma Reflects Accelerated Anabolic Metabolism. Cancer Research, 72(22): 5878-5888
Chu, H.H., Choi, S.H., Ryoo, I., Kim, S.C., Yeom, J.a., Shin, H., Jung, S.C., Lee, L.a., Yoon, T.J., Kim, T.M., Lee, S., Park, C., Kim, J.C., Sohn, C., Park, S., Kim, H.I.l. (2013) Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Radiation Therapy and Concomitant Temozolomide: Comparison Study of Standard and High-b-Value Diffusion-weighted Imaging. Radiology, 269(3): 122024-122024
da Cruz, H.L.C.Jr., Rodriguez, I., Domingues, R.C., Gasparetto, E.L., Sorensen, a.G. (2011) Pseudoprogression and pseudoresponse: Imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol, 32(11): 197885-197885
Easaw, J.C., Mason, W.P., Perry, J., Laperrière, N., Eisenstat, D.D., del Maestro, R., Bélanger, K., Fulton, D., Macdonald, D. (2011) Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Current Oncology, 18(3): 12636-12636
Gahramanov, S., Raslan, A.M., Muldoon, L.L., Hamilton, B.E., Rooney, W.D., Varallyay, C.G., Njus, J.M., Haluska, M., Neuwelt, E.a. (2011) Potential for Differentiation of Pseudoprogression from True Tumor Progression with Dynamic Susceptibility-Weighted Contrast-Enhanced Magnetic Resonance Imaging Using Ferumoxytol vs. Gadoteridol: A Pilot Study. International Journal of Radiation Oncology *Biology* Physics, 79(2): 514-523
Gahramanov, S., Muldoon, L.L., Varallyay, C.G., Li, X., Kraemer, D.F., Fu, R., Hamilton, B.E., Rooney, W.D., Neuwelt, E.a. (2013) Pseudoprogression of Glioblastoma after Chemoand Radiation Therapy: Diagnosis by Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Mr Imaging with Ferumoxytol versus Gadoteridol and Correlation with Survival. Radiology, 266(3): 842-852
Hattingen, E., Lanfermann, H., Quick, J., Franz, K., Zanella, F.E., Pilatus, U. (2009) 1H Mr spectroscopic imaging with short and long echo time to discriminate glycine in glial tumours. Magnetic Resonance Materials in Physics, Biology and Medicine, 22(1): 33-41
Hu, L.S., Eschbacher, J.M., Heiserman, J.E., Dueck, a.C., Shapiro, W.R., Liu, S., Karis, J.P., Smith, K.A., Coons, S.W., Nakaji, P., Spetzler, R.F., Feuerstein, B.G., Debbins, J., Baxter, L.C. (2012) Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro-Oncology, 14(7): 919-930
Jain, M., Nilsson, R., Sharma, S., Madhusudhan, N., Kitami, T., Souza, a.L., Kafri, R., Kirschner, M.W., Clish, C.B., Mootha, V.K. (2012) Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation. Science, 336(6084): 1040-1044
Ken, S., Vieillevigne, L., Franceries, X., Simon, L., Supper, C., Lotterie, J.a., Filleron, T., Lubrano, V., Berry, I., Cassol, E., Delannes, M., Celsis, P., Cohen-Jonathan, E.M., Laprie, A. (2013) Integration method of 3D Mr spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost. Radiation Oncology, 8(1): 1-1
Kong, D.S., Kim, S.T., Kim, E.T., Lim, D.H., Kim, W.S., Suh, Y.L., Lee, J., Park, K., Kim, J.H., Nam, D.H. (2011) Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status. American Journal of Neuroradiology, 32(2): 382-387
Law, M., Yang, S., Babb, J.S., Knopp, E.A., Golfinos, J.G., Zagzag, D., i dr. (2004) Comparison of Cerebral Blood Volume and Vascular Permeability from Dynamic Susceptibility Contrast-Enhanced Perfusion Mr Imaging with Glioma Grade. AJNR Am J Neuroradiol, 25(5): 74655-74655
Lehnhardt, F., Bock, C., Röhn, G., Ernestus, R., Hoehn, M. (2005) Metabolic differences between primary and recurrent human brain tumors: A 1H NMR spectroscopic investigation. NMR in Biomedicine, 18(6): 371-382
Leimgruber, A., Ostermann, S., Yeon, E.J., Buff, E., Maeder, P.P., Stupp, R., Meuli, R.a. (2006) Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. International Journal of Radiation Oncology *Biology* Physics, 64(3): 869-875
Macdonald, D.R., Cascino, T.L., Schold, S.C.Jr., Cairncross, J.G. (1990) Response criteria for phase II studies of supratentorial malignant glioma. Journal of Clinical Oncology, 8(7): 1277-1280
Mangla, R., Singh, G., Ziegelitz, D., Milano, M.T., Korones, D.N., Zhong, J., Ekholm, S.E. (2010) Changes in Relative Cerebral Blood Volume 1 Month after Radiation-Temozolomide Therapy Can Help Predict Overall Survival in Patients with Glioblastoma. Radiology, 256(2): 575-584
Morris, J.G., Grattan-Smith, P., Panegyres, P.K., o'Neill P., Soo, Y.S., Langlands, a.O. (1994) Delayed cerebral radiation necrosis. QJM: An International Journal of Medicine, 87(2): 11929-11929
Nasel, C., Azizi, A., Veintimilla, a., Mallek, R., Schindler, E. (2000) A standardized method of generating time-to-peak perfusion maps in dynamic-susceptibility contrast-enhanced Mr imaging. AJNR Am J Neuroradiol, 21(7): 11958-11958
Neumann-Haefelin, T., Wittsack, H.J., Wenserski, F., Siebler, M., Seitz, R.J., Mödder, U., i dr. (1999) Diffusion-and perfusion-weighted MRI: The DWI/PWI mismatch region in acute stroke. Stroke, 30(8): 15917-15917
Rempp, K.A., Brix, G., Wenz, F., Becker, C.R., Gückel, F., Lorenz, W.J. (1994) Quantification of regional cerebral blood flow and volume with dynamic susceptibility contrast-enhanced Mr imaging. Radiology, 193(3): 637-641
Righi, V., Andronesi, O.C., Mintzopoulos, D., Black, P.M., Tzika, a.A. (2010) High-resolution magic angle spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors. Int J Oncol, 36(2): 3016-3016
Song, Y.S., Choi, S.H., Park, C.K., Yi, K.S., Lee, W.J., Yun, T.J., Kim, T.M., Lee, S.J., Kim, J., Sohn, C., Park, S.K., Kim, H.I.l., Jahng, G., Chang, K. (2013) True Progression versus Pseudoprogression in the Treatment of Glioblastomas: A Comparison Study of Normalized Cerebral Blood Volume and Apparent Diffusion Coefficient by Histogram Analysis. Korean Journal of Radiology, 14(4): 662-662
Sugahara, T., Korogi, Y., Tomiguchi, S., Shigematsu, Y., Ikushima, I., Kira, T., i dr. (2000) Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced Mr imaging for differentiating tumor recurrence from nonneoplastic contrastenhancing tissue. AJNR Am J Neuroradiol, 21(5): 9019-9019
Suh, C.H., Kim, H.S., Choi, Y.J., Kim, N.S., Kim, S.J. (2013) Prediction of Pseudoprogression in Patients with Glioblastomas Using the Initial and Final Area Under the Curves Ratio Derived from Dynamic Contrast-Enhanced T1-Weighted Perfusion Mr Imaging. American Journal of Neuroradiology, 34(12): 2278-2286
Sundgren, P.C. (2009) Mr Spectroscopy in Radiation Injury. American Journal of Neuroradiology, 30(8): 1469-1476
Tsien, C., Galbán, C.J., Chenevert, T.L., Johnson, T.D., Hamstra, D.A., Sundgren, P.C., i dr. (2010) Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol, 28(13): 2293920-2293920
Tugnoli, V., Tosi, M.R., Barbarella, G., Bertoluzza, A., Ricci, R., Trevisan, C. (1996) In vivo 1H Mrs and in vitro multinuclear Mr study of human brain tumors. Anticancer Res, 16(5A): 28919-28919
Verma, N., Cowperthwaite, M.C., Burnett, M.G., Markey, M.K. (2013) Differentiating tumor recurrence from treatment necrosis: A review of neuro-oncologic imaging strategies. Neuro-Oncology, 15(5): 515-534
Wen, P.Y., Macdonald, D.R., Reardon, D.a., Cloughesy, T.F., Sorensen, a.Gregory, Galanis, E., Degroot, J., Wick, W., Gilbert, M.R., Lassman, A.B., Tsien, C., Mikkelsen, T., Wong, E.T., Chamberlain, M.C. (2010) Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology, 28(11): 1963-1972
Ye, Z.C., Sontheimer, H. (1999) Glioma cells release excitotoxic concentrations of glutamate. Cancer Res, 59(17): 438391-438391
Ye, zu-Cheng C., Rothstein, J.D., Sontheimer, H. (1999) Compromised Glutamate Transport in Human Glioma Cells: Reduction-Mislocalization of Sodium-Dependent Glutamate Transporters and Enhanced Activity of Cystine-Glutamate Exchange. Journal of Neuroscience, 19(24): 10767-10777
Young, R.J., Gupta, A., Shah, A.D., Graber, J.J., Chan, T.a., Zhang, Z., Shi, W., Beal, K., Omuro, A.M. (2013) MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clinical Imaging, 37(1): 41-49